Clinical Trials Browser

Completed × Has announcements × Daunorubicin × Clear all

Leukemia, Leukemia, Myeloid, Acute

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 3 Completed

111 enrolled 23 charts 1 FDA

LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00372593 2021-03-24

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3 Completed

1,070 enrolled 18 charts 2 FDA

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT01696084 2020-08-10

301

Phase 3 Completed

309 enrolled 14 charts 1 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01546038 2020-03-03

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2 Completed

255 enrolled 82 charts 1 FDA

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00927498 2013-07-11

A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old

Phase 3 Completed

280 enrolled 1 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

QuANTUM-First

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

301

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old